Christie M Bartels1, Kevin A Buhr, Jerry W Goldberg, Carolyn L Bell, Maja Visekruna, Swapna Nekkanti, Robert T Greenlee. 1. From the Department of Medicine, Rheumatology Section, and Department of Biostatistics, University of Wisconsin School of Medicine and Public Health (UWSMPH), Madison, Wisconsin; Division of Rheumatology, Marshfield Clinic, and Epidemiology Research Center, Marshfield Clinic Research Foundation, Marshfield, Wisconsin; Division of Internal Medicine-Pediatrics, Health East Woodbury Clinic, Woodbury, Minnesota; Division of Internal Medicine, Springfield Clinic, Springfield, Illinois, USA.
Abstract
OBJECTIVE: To examine the mortality and cardiovascular disease (CVD) burden among a population-based cohort of patients with systemic lupus erythematosus (SLE) with previously described late mean onset and low rates of organ-threatening disease. METHODS: This retrospective population-based cohort study investigated incident cases of SLE diagnosed from 1991-2008 and followed through March 2009 to examine rates of death and CVD events: myocardial infarction, stroke, or congestive heart failure hospitalization. Cases were identified using the 1997 update of the 1982 American College of Rheumatology SLE criteria. Searches included electronic records, chart audits, and state death matches, with physician review. Age-matched and sex-matched population comparisons facilitated relative event rate calculations. RESULTS: Seventy incident SLE cases had late mean onset (52 years), with an incidence of 5 cases per 100,000/year. Matched comparisons showed similar baseline rates of hypertension, hyperlipidemia, and diabetes. However, patients with SLE experienced more CVD in the 2 years preceding SLE diagnosis (OR 3.8, 95% CI 1.8, 8.0). The estimated 10-year mortality rates were 26% for SLE subjects versus 19% for comparisons, hazard ratio (HR) 2.1, p<0.01. Adjusted for prior CVD, SLE cases still demonstrated increased hazards of mortality (HR 1.9, p=0.01) and CVD event or death (HR 1.8, p=0.01). CONCLUSION: This incident SLE cohort demonstrated nearly doubled mortality and CVD event hazards compared to age-matched and sex-matched comparisons, even after accounting for higher CVD events in the 2 years preceding SLE diagnosis. This raises research questions regarding delayed SLE diagnosis versus accelerated CVD prior to SLE, particularly in older-onset SLE.
OBJECTIVE: To examine the mortality and cardiovascular disease (CVD) burden among a population-based cohort of patients with systemic lupus erythematosus (SLE) with previously described late mean onset and low rates of organ-threatening disease. METHODS: This retrospective population-based cohort study investigated incident cases of SLE diagnosed from 1991-2008 and followed through March 2009 to examine rates of death and CVD events: myocardial infarction, stroke, or congestive heart failure hospitalization. Cases were identified using the 1997 update of the 1982 American College of Rheumatology SLE criteria. Searches included electronic records, chart audits, and state death matches, with physician review. Age-matched and sex-matched population comparisons facilitated relative event rate calculations. RESULTS: Seventy incident SLE cases had late mean onset (52 years), with an incidence of 5 cases per 100,000/year. Matched comparisons showed similar baseline rates of hypertension, hyperlipidemia, and diabetes. However, patients with SLE experienced more CVD in the 2 years preceding SLE diagnosis (OR 3.8, 95% CI 1.8, 8.0). The estimated 10-year mortality rates were 26% for SLE subjects versus 19% for comparisons, hazard ratio (HR) 2.1, p<0.01. Adjusted for prior CVD, SLE cases still demonstrated increased hazards of mortality (HR 1.9, p=0.01) and CVD event or death (HR 1.8, p=0.01). CONCLUSION: This incident SLE cohort demonstrated nearly doubled mortality and CVD event hazards compared to age-matched and sex-matched comparisons, even after accounting for higher CVD events in the 2 years preceding SLE diagnosis. This raises research questions regarding delayed SLE diagnosis versus accelerated CVD prior to SLE, particularly in older-onset SLE.
Authors: S Manzi; E N Meilahn; J E Rairie; C G Conte; T A Medsger; L Jansen-McWilliams; R B D'Agostino; L H Kuller Journal: Am J Epidemiol Date: 1997-03-01 Impact factor: 4.897
Authors: Ricard Cervera; Munther A Khamashta; Josep Font; Gian Domenico Sebastiani; Antonio Gil; Paz Lavilla; Juan Carlos Mejía; A Olcay Aydintug; Hanna Chwalinska-Sadowska; Enrique de Ramón; Antonio Fernández-Nebro; Mauro Galeazzi; Merete Valen; Alessandro Mathieu; Frédéric Houssiau; Natividad Caro; Paula Alba; Manuel Ramos-Casals; Miguel Ingelmo; Graham R V Hughes Journal: Medicine (Baltimore) Date: 2003-09 Impact factor: 1.889
Authors: Sudumpai Jarukitsopa; Deana D Hoganson; Cynthia S Crowson; Olayemi Sokumbi; Mark D Davis; Clement J Michet; Eric L Matteson; Hilal Maradit Kremers; Vaidehi R Chowdhary Journal: Arthritis Care Res (Hoboken) Date: 2015-05 Impact factor: 4.794
Authors: Aimée Wattiaux; Brittany Bettendorf; Laura Block; Andrea Gilmore-Bykovskyi; Edmond Ramly; Megan E Piper; Ann Rosenthal; Jane Sadusky; Elizabeth Cox; Betty Chewning; Christie M Bartels Journal: Arthritis Care Res (Hoboken) Date: 2020-03 Impact factor: 4.794
Authors: Sarah K Chen; Medha Barbhaiya; Michael A Fischer; Hongshu Guan; Kazuki Yoshida; Candace H Feldman; Karen H Costenbader; Brendan M Everett Journal: Semin Arthritis Rheum Date: 2019-06-11 Impact factor: 5.532
Authors: T P Mikołajczyk; G Osmenda; B Batko; G Wilk; M Krezelok; D Skiba; T Sliwa; J R Pryjma; T J Guzik Journal: Lupus Date: 2015-08-06 Impact factor: 2.911